Group 1 - The core viewpoint of the article is that the institutional investors hold a significant portion of the shares of Laobaixing (老百姓), with a total of 3.70 billion shares, accounting for 48.73% of the total share capital, although this represents a decrease of 3.63 percentage points from the previous quarter [1] - Among public funds, there was an increase in holdings from one fund, Guotai Dajiankang Stock A, while two funds, Southern CSI 1000 ETF and Guotai Medical Health Stock A, saw a decrease in their holdings [1] - A total of 105 public funds did not disclose their holdings in this quarter, including notable funds such as Huaxia CSI 1000 ETF and GF Healthcare Stock A [1] Group 2 - From the perspective of foreign investment, one new foreign institution disclosed its holdings this quarter, which is Hong Kong Central Clearing Limited [2]

Group 1 - The core viewpoint of the news is that Meihao Medical has seen a stock price increase of 5.27%, reaching 23.55 CNY per share, with a total market capitalization of 13.397 billion CNY as of the report date [1] - Meihao Medical, established on July 15, 2010, specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, with its main revenue sources being home respiratory machine components (59.48%), home and consumer electronics components (14.61%), and other medical product components [1] - The company was listed on October 12, 2022, and has a trading volume of 101 million CNY and a turnover rate of 1.17% [1] Group 2 - Among the top circulating shareholders of Meihao Medical, Bosera Fund's Bosera Healthcare Mixed A (050026) has entered the top ten, holding 2.0095 million shares, which accounts for 1.29% of the circulating shares [2] - The fund has achieved a year-to-date return of 11.9% and a one-year return of 5.29%, ranking 5510 out of 8160 and 6755 out of 8026 in its category, respectively [2] - The fund manager, Chen Ximing, has been in position for nearly four years, with the fund's total asset size at 2.704 billion CNY [3]

Core Viewpoint - The BoShi Healthcare Mixed A Fund (050026) reported a profit of 108 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.1206 yuan. The fund's net value growth rate was 5.27%, and its total size reached 2.065 billion yuan by the end of the reporting period [2]. Fund Performance - As of September 3, 2025, the fund's one-year cumulative net value growth rate was 25.24%, ranking 126 out of 136 comparable funds. Over the past three months, the growth rate was 10.46%, ranking 130 out of 138 [5]. - The fund's three-year Sharpe ratio was -0.3329, ranking 101 out of 105 comparable funds, and the maximum drawdown over the past three years was 35.45%, ranking 75 out of 107 [24][26]. Fund Holdings and Valuation - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 43.58 times, significantly lower than the industry average of 120.96 times. The weighted average price-to-book (P/B) ratio was 3.27 times, compared to the industry average of 4.07 times [10]. - The fund's weighted average revenue growth rate for the first half of 2025 was 0.02%, while the weighted average net profit growth rate was -0.03% [16]. Fund Management and Strategy - The fund manager, Chen Ximing, oversees three funds, all of which have shown positive returns over the past year. The BoShi Healthcare Mixed A Fund is focused on long-term investments in pharmaceutical and healthcare stocks [2]. - The fund management indicated that the innovative drug sector in the Hong Kong stock market remains strong, benefiting from favorable liquidity conditions and superior quality of companies. They expect continued opportunities in the pharmaceutical industry, especially with a potential policy recovery in China [2]. Fund Composition - As of June 30, 2025, the fund's total assets amounted to 2.065 billion yuan, with 211,300 holders collectively owning 861 million shares. Individual investors accounted for 99.72% of the holdings [31][34]. - The top ten holdings of the fund included companies such as DiZhe Pharmaceutical, Zejing Pharmaceutical, and Hengrui Medicine [39].

Core Viewpoint - The report highlights a positive performance in the pharmaceutical sector, particularly in the innovative drug industry, driven by ongoing licensing agreements and supportive domestic policies [3]. Fund Performance - The fund reported a profit of 26.97 million yuan in Q2 2025, with a weighted average profit per fund share of 0.0627 yuan [2]. - The fund's net asset value (NAV) growth rate for Q2 was 7.62%, and the fund size reached 375 million yuan by the end of Q2 [2][16]. - As of July 18, the fund's unit NAV was 0.96 yuan [2]. - The fund's performance over the past three months showed a NAV growth rate of 14.74%, ranking 112 out of 138 comparable funds [4]. - Over the past six months, the fund's NAV growth rate was 25.40%, ranking 100 out of 138 [4]. - The one-year NAV growth rate was 24.99%, also ranking 100 out of 133 [4]. - The three-year NAV growth rate was 4.99%, ranking 46 out of 107 [4]. Investment Strategy - The fund manager expressed optimism about the innovative drug sector, indicating a shift from a general revaluation phase to a stage where actual performance and partnerships will be tested [3]. - The strategy includes a "barbell" approach, focusing on high-probability or high-return innovative drug companies [3]. - The fund is also looking at sectors with strong performance, such as orthopedics and upstream innovative drugs, while making early allocations in improving sectors like medical devices [3]. - New technologies like AI and brain-computer interfaces are expected to transform the healthcare system, although short-term financial impacts on related companies may be limited [3]. Risk and Return Metrics - The fund's three-year Sharpe ratio was 0.1406, ranking 41 out of 105 comparable funds [9]. - The maximum drawdown over the past three years was 29.8%, ranking 97 out of 106 [11]. - The fund's average stock position over the past three years was 85.43%, slightly below the comparable average of 86.95% [14].